IndustryCompany release

Sana Biotechnology reports $121.7M cash and targets SC451 diabetes IND and Phase 1/2 start

🇺🇸 Sana Biotechnology, Inc. (SANA) · Thu 05 Nov 2026

The US cell therapy developer says its cash runway extends into mid-2027 and that SC451, a hypoimmune islet therapy for type 1 diabetes, could enter the clinic as early as this year.

Sana Biotechnology reported its third-quarter 2026 results on 5 November, disclosing cash of $121.7M. The company said this should fund operations into mid-2027.

The main clinical milestone is SC451, a hypoimmune, iPSC-derived islet cell therapy for type 1 diabetes. Sana expects to file an investigational new drug (IND) application and begin a Phase 1/2 trial as early as this year. The company did not provide further detail in the information available.

Sana also expects to start a clinical study of SG293 in non-Hodgkin lymphoma in the first quarter of 2027.

The company pointed to a letter in the New England Journal of Medicine reporting 14-month islet data for UP421. It also said its collaboration with the Mayo Clinic is advancing. No further data or terms of the collaboration were included in the material reviewed.

As general context, an IND application allows a sponsor to begin human trials of an investigational product in the US. Under the FDA process, a study can generally proceed once the 30-day review period passes without a clinical hold.

What it means for your team

  • Regulatory teams tracking cell therapies should watch for an SC451 IND submission, which Sana says could come as early as this year.
  • An SG293 lymphoma study is planned for 1Q 2027, so a second Sana programme may reach the clinic within months.
  • Cash into mid-2027 sets a financing horizon that partners and competitors in iPSC-derived and hypoimmune approaches may track.
  • The 14-month UP421 islet data and the Mayo Clinic collaboration are signals to monitor for evidence in this field.

Company's press release (SEC filing): Sana Biotechnology, Inc. ↗

Article written by VigiEye from the official source (Sana Biotechnology, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →